4- (4- (4- chlorophenyl)- 4- hydroxy- 1- piperidinyl)- 1- (4- fluorophenyl)- 1- butanol

01/01/1990 - "Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia."
01/01/1989 - "Hydroxyhaloperidol and clinical outcome in schizophrenia."
09/01/2000 - "Comment on 'reduced haloperidol does not interfere with antipsychotic activity of halperidol in the treatment of acute schizophrenia'."
07/01/1999 - "It is concluded that serum concentrations of reduced haloperidol are of minor value for the interpretation of data of therapeutic drug monitoring of haloperidol in patients with acute schizophrenia. "
03/01/1994 - "Correlation of clinical response (PANSS) and plasma levels of haloperidol and reduced haloperidol in schizophrenia."

07/03/1995 - "Injection of haloperidol and reduced haloperidol 1, 3 and 10 days earlier exacerbated the dystonic response by decreasing the latency to maximal dystonia and increasing the duration of the response at each dose tested compared with saline-treated animals. "
01/01/1987 - "Pargyline caused no changes in baseline behaviors, but significantly reduced haloperidol-induced acute dystonia (AD) (-67%, P less than 0.002) and parkinsonism (-56%, P less than 0.005). "
07/03/1995 - "Haloperidol and reduced haloperidol-induced exacerbation of the dystonia produced by the kappa opioid U50,488H in guinea-pigs is associated with inhibition of sigma binding sites: behavioural and autoradiographical studies."

09/30/2011 - "THIM-exposed rats also manifested reduced haloperidol-induced catalepsy, accompanied by a marked decline in the density of striatal D₂ receptors, measured by immunohistochemical staining, suggesting alterations to the brain dopaminergic system. "
07/01/2004 - "Furthermore, antagonizing the A(2A) receptor (R) reduced haloperidol induced catalepsy. "
01/01/2002 - "The non-competitive antagonist of receptor subtype 5 (mGluR5), MPEP (1.0-10 mg/kg ip), or the agonist of group II mGluRs, LY354,740 (5-10 mg/kg ip), reduced haloperidol-induced muscle rigidity and catalepsy. "
01/01/2023 - "In vivo, dipraglurant dose-dependently reduced haloperidol-induced catalepsy, increased punished licks in the Vogel conflict-drinking model, decreased immobility time in the forced swim test, decreased the number of buried marbles in the marble-burying test, but had no effect on rotarod performance or locomotor activity. "
01/01/1997 - "The motor effects of all the reduced haloperidol and bromoperidol metabolites were evaluated by the mouse catalepsy test. "

07/01/2009 - "Subcutaneous administration of haloperidol or its metabolites I or II (reduced haloperidol) dose-dependently reversed capsaicin-induced (1 microg, intraplantar) mechanical hypersensitivity of the hind paw (stimulated with a nonpainful, 0.5-g force, punctate stimulus). "
07/25/1980 - "These results clearly demonstrate that amantadine greatly reduced haloperidol-induced striatal dopamine receptor hypersensitivity and support the hypothesis that amantadine given concurrently with neuroleptic agents might serve to prevent the development of human tardive dyskinesia."

06/01/2000 - "The Css of haloperidol and reduced haloperidol were measured in duplicate by high performance liquid chromatographic method, and were corrected to the mean body weight. "
05/01/2013 - "TAAR1 agonists do not induce catalepsy or weight gain; RO5263397 even reduced haloperidol-induced catalepsy and prevented olanzapine from increasing body weight and fat accumulation. "